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Autoantibodies in the sera of patients with primary biliary cirrhosis, shown previously to recognise the E2 polypeptide 
of the mammalian pyruvate dehydrogenase complex (PDC), have been demonstrated to react with the E2 component 
of PDC from bacteria (E. coli) and yeast (S. cerevisiae). Limited tryptic digestion, which cleaves E2 into well-characterised 
domains, followed by Western blotting indicates that the main immunodominant region of PDC E2 lies within the lipoic 
acid-containing domains of the polypeptide. 
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1. INTRODUCTION 
Primary biliary cirrhosis is a chronic, pro- 
gressive cholestatic liver disease characterised by 
inflammatory obliteration of the intrahepatic bile 
ducts leading to fibrosis, cirrhosis and ultimately 
to liver failure [1]. PBC is the commonest indica- 
tion for liver transplantation i Europe [2]. The 
cause remains unknown but there is considerable 
evidence for an autoimmune process [3], in par- 
ticular a marked expansion of B lymphocyte clones 
producing highly specific AMA [4]. These autoan- 
tibodies are routinely demonstrated in the serum of 
patients with PBC by indirect immunofluorescence 
[5], and are directed against trypsin-sensitive an- 
tigens termed M2, associated with the inner 
mitochondrial membrane [6]. M2 mitochondrial 
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antigens are known to be non-organ-specific, non- 
species-specific and highly conserved in evolution, 
with unidentified bacterial and yeast proteins 
cross-reacting with PBC autoantibodies [7,8]. 
Recently we have identified four of the M2 au- 
toantigens as the E2 components of PDC, OGDC 
and BCOADC, as well as the protein X component 
of PDC [9,10]. Others have also reported that 
PDC E2 is an autoantigen [11,12]. 
E2 has an essential structural and catalytic role 
in the complexes. It forms a central symmetrical 
core to which El and E3 are bound and contains 
a covalently-attached lipoic acid cofactor which in- 
teracts with the active sites of each component en- 
zyme [13]. The structure of E2 is consistent with 
these two properties, comprising a compact inner 
core domain containing the catalytic and subunit- 
binding sites, and one or more extended outer do- 
mains containing the lipoic acid moiety. Stretches 
of flexible polypeptide rich in alanine and proline 
residues link the different domains and contain 
trypsin-sensitive sites where E2 can be cleaved into 
separate functional domains [14,15]. 
In this communication we Iocalise the major im- 
munodominant region on the mammalian E2 
polypeptide and demonstrate that the E2 com- 
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ponents of yeast and bacterial PDC are recognised 
by PBC patients' sera. 
2. MATERIALS AND METHODS 
2.1. Materials 
[2-~4C]Pyruvate was obtained from New England Nuclear. 
PDC was purified from bovine heart essentially as in [16]. E2 
and protein X of PDC, which copurify with each other, were 
obtained by resolution of the complex using gel filtration on 
Superose 6 (Pharmacia) in the presence of 1 M NaC1 [9]. 
Chicken liver H-protein was obtained from Professor Y. 
Motokawa (University of Tokushima, Japan), E. coli PDC 
from Professor J. Guest (University of Sheffield, England) and 
yeast (S. cerevisiae) PDC from Dr J. Gordon Lindsay (Universi- 
ty of Glasgow, Scotland). 
2.2. Acetylation of  PDC E2 
PDC E2 (2 mg/ml, containing approx. 10% of protein X) 
was incubated at 25°C in 50 mM potassium phosphate, 1 mM 
EDTA, pH 6.5, with 0.2 mg/ml PDC El, 0.4 mM thiamine 
pyrophosphate, 2 mM MgC12, 0.5 mM N-ethylmaleimide and 
0.2 mM [2-14C]pyruvate (30000 cpm/nmol). Incorporation of 
[14C]acetyl groups into protein was measured on filter paper 
discs as in [17]. After incubation for 30 min, dithiothreitol was 
added to a final concentration f 1.5 mM, and the labelled pro- 
tein was digested with trypsin (1% w/w). 
2.3. SDS-PAGE and imrnunoblotting 
Samples of digested protein were subjected to polyacrylamide 
gel electrophoresis in the presence of SDS (SDS-PAGE) on 10% 
gels [18], and duplicate samples were then subjected to 
autoradiography, or electrophoretically transferred to nitro- 
cellulose [19]. After blocking and washing, individual anes 
were incubated with human sera at a dilution of between 1: 100 
and 1 : 1000. Detection of human lgG antibodies was by means 
of secondary goat anti-human IgG (7-chain specific) peroxi- 
dase-conjugated antibodies (Sigma), with 4-chloro-l-naphthol 
as substrate [9]. 
Thirty-eight serum samples known to contain AMA directed 
against PDC E2 were obtained from PBC patients, and thirty- 
nine serum samples, negative for AMA by immunofluores- 
cence, were obtained from patients with other chronic liver 
diseases and from healthy normal women. Clinical and 
laboratory data on these patients and controls have been given 
previously [9]. 
3. RESULTS AND DISCUSSION 
When purified bovine PDC was incubated in the 
presence of [2-14C]pyruvate and N-ethylmale- 
imide, the E2 and X components became rapidly 
acetylated, accompanied by a slower loss of activi- 
ty of the complex due to modification by N-ethyl- 
maleimide of the free-thiol group generated by the 
reductive acylation of the lipoic acid. However the 
presence of the E1 and E3 component enzymes 
bound to the assembled complex rendered E2 
somewhat resistant to subsequent proteolysis by 
trypsin (not shown). Hence, [14C]acetyl groups 
were incorporated into the purified E2-X sub- 
complex by incubation with [2-~4C]pyruvate in the 
presence of N-ethylmaleimide and approximately 
two pyruvate dehydrogenase (PDC El) tetramers 
per E2 core. The E2 and X components became 
rapidly acetylated as judged by the incorporation 
of trichloroacetic acid-precipitable radioactivity 
and by SDS-PAGE and autoradiography. After 
labelling, the acetylated components were sub- 
jected to digestion with 1070 (w/w) trypsin, the 
reaction being stopped by addition of excess tryp- 
sin inhibitor. Fig.1 shows the time course of this 
tryptic digestion. After 1-2 h digestion, two major 
proteolytic fragments are produced from E2 with 
apparent molecular masses of approximately 37 
and 28 kDa as visualised by staining with 
Coomassie blue (fig.la). One major radioactive 
band was produced corresponding to the lipoyl- 
containing domain with an apparent molecular 
mass of approx. 37 kDa (fig.lb). This is consistent 
with previously published data [14]. A minor 
radioactive band, migrating at the dye front, cor- 
responds to the lipoyl-containing domain(s) of 
protein X. 
When 1/zg of trypsin-cleaved E2 (and X) was 
immunoblotted against sera from PBC patients at 
a dilution of 1 : 1000 it was found that in all cases 
(38/38) the antibodies bound exclusively to the 
lipoyl-containing domain (fig.2) and not to any 
other major proteolytic fragment, indicating that 
the immunodominant region lies within that do- 
main. (Reactivity to the lipoate domain of protein 
X could not be demonstrated using the 10°70 
polyacrylamide g l system, due to the presence of 
the coloured dye. However, when a 15°70 gel 
system was employed, PBC sera were shown to 
cross-react with this fragment (not shown).) None 
of the sera from the 39 control subjects howed 
reactivity with any fragment. 
Lipoic acid has been shown to be a mitogen, 
augmenting antibody responses in vitro [20] and 
restoring antibody responses in immunosuppressed 
mice [21]. The finding that the immunodominant 
region is located within the lipoyl-containing do- 
main prompted us to investigate the possible role 
of lipoic acid in antibody binding. Firstly, in the 
immunoblotting procedure 1 mM lipoic acid, 
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Fig.1. Time course of tryptic digestion of 14C-labelled E2. E2 
was acetylated in the presence of [2-t4C]pyruvate, N- 
ethylmaleimide and trace amounts of PDC El ,  as in section 2, 
and dithiothreitol was then added to a final concentration of 
1.5 raM. [14C]E2 (2 mg/ml) was incubated with trypsin 0% 
w/w) at 4°C and 13/~l aliquots were taken at the times indicated 
and added to 28 Fl soybean trypsin inhibitor (5 mg/ml) and 
20/~1 Laemmli's sample buffer. Samples of digested protein 
were subjected to SDS-PAGE on 10% gels, and subsequently 
autoradiographed. (a) The resultant SDS gel stained with 
Coomassie brilliant blue R, and (b) the corresponding 
autoradiograph. E2 and X are intact component enzymes; L, 
the lipoyl-containing domain of E2; and C, the E2 structural 
core domain. 
1 mM lipoamide and a combination of the two 
were added to the incubation with sera for 2 h 
allowing binding, but this did not absorb out the 
reactivity (not shown). Secondly, we tested chicken 
liver H-protein, a 13.9 kDa component of the 
mitochondrial glycine cleavage system [22,23] for 
cross-reactivity in immunoblotting, as this is the 
only other protein, apart from the E2 components 
of the 2-oxo acid dehydrogenase complexes, 
known to contain a covalently-bound lipoic acid. 
There was no recognition of this protein by au- 
toantibodies in the PBC patients' sera, even at a 
Fig.2. Reactivity of PBC sera with the domain of PDC E2 
produced by tryptic digestion. 14C-acetylated E2 was subjected 
to proteolysis by trypsin for 4h ,  as in rigA. Lanes: 1, 
nitrocellulose (10/~g of protein) stained with Amido black; 2,3, 
nitrocellulose (1 ~g of protein) incubated with PBC sera at a 
dilution of ! : 1000 (2), or control sera at a dilution of l : 100 (3), 
as in section 2. 
greatly increased loading of polypeptide (20/~g of 
H-protein compared to 1/~g of PDC E2). This in- 
dicates that some structural aspect unique to the 
lipoyl domain of the E2 components i important 
with respect o antigenicity, rather than reactivity 
being confined to recognition of lipoic acid alone. 
In this regard it is of interest hat there is signifi- 
cant primary sequence homology around the 
lipoic-acid attachment site of mammalian and 
bacterial PDC E2, but less homology with the cor- 
responding region from chicken liver H-protein 
[17]. 
In view of the known reactivity of PBC sera with 
yeast and bacterial proteins [7,8], and the recent 
identification of E2 of mammalian PDC as an M2 
autoantigen, the possible cross-reactivity of pa- 
tients' sera with PDC purified from E. coli and 
yeast was investigated. Fig.3 shows that the au- 
toantibodies in PBC sera react with the E2 com- 
ponents of the pyruvate dehydrogenase complex 
from these organisms. In the case of the yeast com- 
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autoantibodies lies within the l ipoyl-containing do- 
main which is located on the surface of this large 
mult ienzyme complex. Further analysis of the 
precise nature of the antigenic element(s) in the au- 
toantigens may be important in understanding the 
immunopathogenesis of PBC and the mechanisms 
of self-tolerance at the molecular level. 
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Fig.3. Reactivity of PBC sera with the E2 components of 
bacterial, yeast and mammalian PDC. Proteins were subjected 
to SDS-PAGE, transferred to nitrocellulose and immuno- 
blotted with PBC sera (dilution of 1:1000) as in section 2. 
Lanes: 1, E. coli PDC (2/~g protein); 2, S. cerevisiae PDC (2/tg 
protein); 3, bovine heart PDC E2 and X (0.5/~g protein). 
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